NaviFUS
Taiwan - Taipei CBiotechnology
Focus: NaviFUS is a Taiwan-based biotech company specializing in non-invasive focused ultrasound systems for blood-brain barrier opening and targeted drug delivery, primarily focused on neurology indications. Founded in 2021, the company is early-stage with a pipeline focused on glioblastoma and drug-resistant epilepsy.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Open Jobs
0
About NaviFUS
AI assessmentNot HiringNo open roles listed right now. Follow NaviFUS to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
NaviFUS System
GBMClinical Trials (1)
NCT07274787Safety And Effectiveness Of NaviFUS System With Bevacizumab In Recurrent Glioblastoma
N/AHelp build intelligence for NaviFUS
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.